BioNxt Commences GMP Manufacturing for Multiple Sclerosis Treatment

BioNxt Solutions Inc., based in Vancouver, has announced the completion of Good Manufacturing Practice (GMP) manufacturing for its sublingual Cladribine oral thin film. This marks an important step in their lead program, targeting relapsing multiple sclerosis (MS) and other neurodegenerative diseases. Conducted in Munich, Germany, the GMP batch will supply BioNxt's upcoming clinical trial, comparing their formulation to the reference product, Mavenclad®.

The manufacturing aligns with EU GMP standards and incorporates validated processes, furthering BioNxt's readiness for human clinical trials. With initiation of stability studies, the company is positioned for first-in-human dosing, reducing operational risks in development and bolstering regulatory readiness.

BioNxt's sublingual Cladribine film aims to improve drug delivery by bypassing gastrointestinal absorption issues and offering a patient-friendly alternative. The collaboration with the Munich-based CDMO enhances BioNxt's manufacturing capabilities, supporting future studies and potential commercial production.